Equities

SanBio Co Ltd

4592:TYO

SanBio Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)1,295.00
  • Today's Change213.00 / 19.69%
  • Shares traded11.77m
  • 1 Year change+87.95%
  • Beta1.2335
Data delayed at least 20 minutes, as of Sep 20 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in JPYIncome statement in JPYView more

Year on year SanBio Co Ltd had revenues remain flat at 0.00, though the company grew net income from a loss of 5.56bn to a smaller loss of 2.64bn.
Gross margin--
Net profit margin--
Operating margin--
Return on assets-51.36%
Return on equity-113.96%
Return on investment-67.07%
More ▼

Cash flow in JPYView more

In 2024, cash reserves at SanBio Co Ltd fell by 2.29bn. Cash Flow from Financing totalled 2.37bn or -- of revenues. In addition the company used 4.77bn for operations while cash used for investing totalled 19.03m.
Cash flow per share-32.07
Price/Cash flow per share--
Book value per share22.91
Tangible book value per share22.27
More ▼

Balance sheet in JPYView more

SanBio Co Ltd appears to have a strong balance sheet with enough cash in the capital structure to pay down 100% of the liabilities.
Current ratio5.30
Quick ratio--
Total debt/total equity0.3378
Total debt/total capital0.2525
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.